OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
PEN
Penumbra, Inc.
PEN has a slight edge over OSCR overall, supported by lower modeled downside and stronger valuation.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
PEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PEN in the historical PE scenario, which offers more potential upside but is not a forecast.
PEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 55x | $321 | — |
| Cheap | 76x | $300 | -6.4% |
| Current | 81x | $321 | — |
| Fair | 222x | $883 | +175% |
| Expensive | 648x | $2,574 | +702% |
Historical ranges are pointers, not guarantees.
PEN's PE is in its cheap range at 81x. If earnings grow as analysts expect, today's price would be 55x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PEN, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
PEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.82 | +47% |
| Q3 2026 | $3.97 | -5.5% |
| Q2 2026 | $4.07 | +7.7% |
| Q1 2026 | $4.34 | +302% |
| Q4 2025 | $4.52 | +1156% |
| Q3 2025 | $4.20 | +388% |
| Q2 2025 | $3.78 | +1012% |
| Q1 2025 | $1.08 | -54% |
| Q4 2024 | $0.36 | -84% |
PEN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $410.1M | +16% |
| Q2 2026 | $390M | +15% |
| Q1 2026 | $374.8M | +16% |
| Q4 2025 | $385.4M | +22% |
| Q3 2025 | $354.7M | +18% |
| Q2 2025 | $339.5M | +13% |
| Q1 2025 | $324.1M | +16% |
| Q4 2024 | $315.5M | +11% |
PEN's revenue has grown year over year every quarter since late 2020: $410M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -1.4 points |
| Q2 2026 | 11% | -1.5 points |
| Q1 2026 | 10% | -2.3 points |
| Q4 2025 | 15% | +1.8 points |
| Q3 2025 | 14% | +2 points |
| Q2 2025 | 12% | +39 points |
| Q1 2025 | 12% | +8.1 points |
| Q4 2024 | 14% | +1.3 points |
PEN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
PEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | -37% |
| Q2 2026 | $32.5M | +11% |
| Q1 2026 | $73.3M | +106% |
| Q4 2025 | $68.1M | +49% |
| Q3 2025 | $42M | -18% |
| Q2 2025 | $29.4M | +62% |
| Q1 2025 | $35.5M | +9.3% |
| Q4 2024 | $45.7M | +40% |
PEN generated $200M in free cash flow over the past year, up 31% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +48.2K shares |
| 1 year | +0.8% | +318K shares |
| 3 years | +1% | +400K shares |
| 5 years | +5.3% | +2M shares |
| Available history | +9.1% | +3.3M shares |
PEN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $1,000 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PEN on leverage, with a lower net debt burden relative to earnings.
PEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -1.7x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.4x | Net Cash |
| Q4 2024 | -9.8x | Net Cash |
PEN has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 27.1 | Neutral |
PEN's weekly RSI is 51 (neutral) and its Stochastic is 27 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PEN on valuation relative to its sector.
PEN PE vs Healthcare Sector
| Metric | PEN | Sector median | Relative |
|---|---|---|---|
| PE | 81x | 26x | 213% above |
| PE % | 26 | 29 | 3 pts below |
PEN is trading at 81x earnings, a 213% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PEN on trend strength, trading above more of its moving averages.
PEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.0 | 0.2% above |
| 20 week MA | $320.6 | 0.1% above |
| 50 week MA | $325.6 | 1.5% below |
| 100 week MA | $294.7 | 8.8% above |
| 200 week MA | $267.7 | 20% above |
PEN's trend is mixed: it's above four of its five weekly moving averages, and 20% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PEN on returns for 2026, with the stronger performance.
PEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $164.1 | $187.4 | +14% |
| 2021 | $187.4 | $275.6 | +47% |
| 2022 | $275.6 | $219.6 | -20% |
| 2023 | $219.6 | $251.5 | +15% |
| 2024 | $251.5 | $239.9 | -4.6% |
| 2025 | $239.9 | $317.0 | +32% |
| 2026 YTD | $317.0 | $320.8 | +1.2% |
PEN has finished higher in four of the last six years. It's up 1.2% so far in 2026.